Pfizer Centers for Therapeutic Innovation 2017
We are pleased to alert you to a call for proposals for Pfizer’s Centers for Therapeutic Innovation (CTI) program for the development of biotherapeutics for the treatment of various diseases. CTI supports translational programs in the therapeutic areas of Inflammation and immune disorders, Oncology, Rare monogenic genetic diseases, Neuroscience, Cardiovascular and metabolic diseases.
Spring 2017: Cycle 1
- Deadline for PIs to submit a 2-3 page preproposal to Partners Innovation office is: Monday, April 24, 2017
Fall 2017: Cycle 2
- Information on Cycle 2 will be provided later this year.
Who Should Apply: Researchers working with validated drug targets that are tractable with biologic modalities such as antibodies, peptides, proteins, ADCs and/or Fusion proteins, who are interested in developing a novel therapeutic agent to address an unmet clinical need should apply. Pfizer may fund 1 to 3 postdoctoral fellows for 2 to 3 years per project. Any intellectual property covering the newly developed therapeutic will be jointly owned by the Partners entity and CTI. Background intellectual property is not necessary for submission, but access to it may be required, if it exists.
The process: Preproposals should be submitted via email to Partners Innovation at: firstname.lastname@example.org. Please use the Preproposal Template (see link below). Innovation will conduct a review of each preproposal to ensure that no confidential or proprietary information is included, prior to forwarding to CTI. CTI will make the decisions on which preproposals to advance to a full proposal stage. Invitations will then be sent to the PI‘s to submit confidential full proposals, to be developed together with CTI personnel. Funding decisions on full proposals will be made by the CTI Partners Joint Steering Committee.
Enclosed are links to documents which provide additional detail:
Partners_CTI LargeMol Flyer Cycle 1 2017 finalv2
CTI-Pre-Proposal-Template_LM for 2017
If you have any questions regarding the program, please contact Seema Basu at email@example.com.